Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This single-arm, Phase II, multicenter study was designed to evaluate the safety and efficacy
of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) in combination with
Apatinib+carboplatin plus (+) etoposide in chemotherapy-naive participants with ES-SCLC.
Participants will be receive camrelizumab +apatinib+ carboplatin + etoposide on 21-day cycles
for four -six cycles in the induction phase followed by maintenance with camrelizuab
+apatinib until progressive disease (PD) as assessed by the investigator using Response
Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued
until persistent radiographic PD or symptomatic deterioration.